Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

SELECTED QUARTERLY FINANCIAL DATA (Tables)

12 Months Ended

Dec. 31, 2013

	Year Ended December 31, 2013												Year Ended December 31, 2012

	Q1			Q2			Q3			Q4			Q1			Q2			Q3			Q4
	(unaudited, in thousands, except per share amounts)
Revenue	$	—		$	1,400		$	—		$	5,750		$	750		$	1,500		$	—		$	—
Net loss	$	(25,574	)	$	(22,768	)	$	(23,824	)	$	(16,861	)	$	(23,174	)	$	(24,738	)	$	(25,456	)	$	(25,472	)
Net loss per share, basic and diluted	$	(0.29	)	$	(0.26	)	$	(0.27	)	$	(0.19	)	$	(0.32	)	$	(0.35	)	$	(0.36	)	$	(0.30	)
Weighted average shares used in computing net loss per share, basic and diluted		87,141			87,147			87,430			87,430			71,422			71,458			71,636			85,274